Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
In Reply: The extraordinary variability in
prostate cancer clinical outcomes poses a significant challenge to anyone
counseling patients about treatment for clinically localized disease. Clinicians
have relied on stage and grade to quantify prognosis accurately. Gleason and
Mellinger and members of the Veterans Administration Cooperative Urological
Research Group developed a low-power scoring system that standardized prostate
cancer readings worldwide.1 Unfortunately,
as indicated by Dr Koss, the system is inherently subjective and therefore
prone to differing interpretations. In its place, Dr Koss suggests an analysis
of DNA content.
Albertsen PC, Hanley JA, Fine J. Localized Prostate Cancer and DNA Ploidy—Reply. JAMA. 2005;294(10):1207-1208. doi:10.1001/jama.294.10.1207-b